1. Home
  2. BGLC vs GRI Comparison

BGLC vs GRI Comparison

Compare BGLC & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$1.47

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.00

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
GRI
Founded
2017
2018
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.5M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BGLC
GRI
Price
$1.47
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
9.0K
385.5K
Earning Date
04-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
N/A
EPS
N/A
N/A
Revenue
$7,424,911.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.18
52 Week High
$6.10
$6.70

Technical Indicators

Market Signals
Indicator
BGLC
GRI
Relative Strength Index (RSI) 42.67 58.36
Support Level $1.22 $1.71
Resistance Level $1.88 $2.30
Average True Range (ATR) 0.11 0.15
MACD 0.00 0.02
Stochastic Oscillator 35.94 77.55

Price Performance

Historical Comparison
BGLC
GRI

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: